Clostridium novyi type A (C. novyi type A)

Clostridium novyi type A is a Gram-positive, spore-forming, obligate anaerobic bacterium that is a significant pathogen in humans and animals, primarily causing gas gangrene (myonecrosis) (Wikipedia, 2024) [2.4.1]. Its virulence is largely attributed to the production of several toxins, most notably the alpha-toxin (TcnA), which is a large clostridial glucosylating toxin (NIH, 2022) [2.2.1]. This toxin acts as an enzyme that inactivates host Rho-family GTPases through N-acetylglucosamination, leading to the disruption of the cytoskeleton, cell rounding, and eventual cell death (NIH, 2022) [2.2.1]. In clinical practice, C. novyi type A is a target for various antimicrobial therapies, including antibiotics like penicillin and metronidazole, which aim to eliminate the vegetative bacteria and prevent toxin production (Wikipedia, 2024) [2.4.1]. Experimental antitoxins are also used to neutralize the lethal effects of the alpha-toxin during active infection (NIH, 1989) [2.2.3]. Additionally, a non-toxic derivative, Clostridium novyi-NT, has been developed as an oncolytic agent that selectively germinates in the hypoxic and necrotic regions of solid tumors (NIH, 2016) [2.3.1]. This therapeutic strain induces direct tumor lysis and stimulates a potent anti-tumor immune response, representing a novel approach in cancer immunotherapy (NIH, 2016) [2.3.1].

Other names

Clostridium oedematiens type AC. novyi ATcnA-producing Clostridium novyiBacillus oedematiens

Inhibition of bacterial cell wall synthesis; Inhibition of bacterial DNA synthesis; Inhibition of bacterial protein synthesis; Neutralization of alpha-toxin